Navigation Links
Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
Date:10/27/2010

NEWTOWN, Pa., Oct. 27 /PRNewswire/ -- Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell® name:

  • Cell-Ess™ Serum Replacement cell culture medium,
  • Cryo-Ess™ cryopreservation medium, and
  • Clin-Ess™ transportation medium.

"The quality and consistency of Cell-Ess, Cryo-Ess and Clin-Ess gives scientists the confidence to conduct their research without testing each new serum lot purchased, resulting in improved laboratory efficiency and valuable cost savings," said Allan Weber, chief executive officer of Essential Pharmaceuticals.  "Moreover, we believe that the characteristics of these media products offer important clinical benefits, making Cell-Ess the ideal choice for use in the cutting edge areas of stem cell, cancer and vaccine research, and Clin-Ess in the preservation of limbs and organs for surgical applications."  

The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers the advantage of superior performance compared to fetal bovine serum. They are free of all animal components and dimethyl sulfoxide (DSMO), do not crystallize or form ice during the thawing process, resulting in less DNA and RNA degradation and fewer artifacts than those preserved using conventional methods. Further, they have demonstrated synthetic reproducibility with no lot-to-lot variability.  

Essential Pharmaceuticals acquired exclusive worldwide rights to these media products, originally the LiforCell® family of products, from Lifeblood Medical, Inc. These cell culture and cryopreservation products have been re-branded to correlate to their specific research and clinical applications.  

"Essential Pharmaceuticals is known for its outstanding customer support in highly specialized fields," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical. "That, along with the superior advantages of these cell culture and cryopreservation media, will generate increased growth and market penetration of the Lifeblood technology."

About Essential Pharmaceuticals

Essential Pharmaceuticals LLC, a key company in the organ transplant arena, provides Custodiol® HTK organ preservation solution to the transplant medical community.  Essential is well-known for excelling in highly specialized medical areas through a combination of outstanding customer support coupled with customized distribution systems and ongoing research projects to further knowledge in the field of organ preservation.  Essential plans on bringing this proven model to support medical researchers and further their projects, improving future medical discoveries globally.

For additional information about Essential Pharmaceuticals new family of cell media products, or any other Essential product, please visit our website at www.essentialpharma.com, e-mail to info@essentialpharma.com or call 1-267-757-0112.

*CUSTODIOL® HTK is a registered trademark of Dr. Franz Kohler Chemie GmbH, Alsbach-Hahnlein, Germany.

*LiforCell® is a registered trademark of Lifeblood Medical, Inc.


'/>"/>
SOURCE Essential Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Laerdal Introduces SimMan Essential
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
5. Weekly Digests Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 Swine Flu Outbreak
6. Essentialis to Submit SPA for Hypertriglyceridemia
7. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
8. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
9. Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
10. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
11. Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
(Date:12/8/2016)...  A new study by a pair of Geisinger ... therapy to treat chronic pain is not only ineffective, ... consequences, including death. Palliative care physicians ... , M.D., authored the study which provides a review ... study was published in the December 2016 edition of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):